Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACER 0.66 0.00(0.00%)
Will ACER be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACER based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACER
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
Acer Therapeutics Inc. (ACER) Gains But Lags Market: What You Should Know
ACER: What are Zacks experts saying now?
Zacks Private Portfolio Services
ACER's Stock Down on Failure of Phase II Study, Cash Updates
Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know
Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know